The most commonly reported adverse effects are the GI symptoms associated with tirzepatide (nausea, reduced appetite) plus the mild headache occasionally seen with AOD 9604
Common signs include: Fatigue and weakness Neurological changes, such as numbness or tingling in the hands and feet Megaloblastic anemia, characterized by large, abnormal red blood cells Cognitive difficulties, including memory loss and confusion Early detection and treatment of B12 deficiency can make a big difference
While GLP-1s have undergone extensive human trials and are licensed by the MHRA, the UK's medicines watchdog, there is a "grey market" of other peptides emerging
Externe Auslser sind UV-Strahlung und hohe Ozonwerte, Umweltgifte und Schadstoffe, Nikotin, Alkohol, Medikamente und eine ungesunde Ernhrung